Abstract
Piperacillin/tazobactam (TZP) is a commonly prescribed antibiotic. Here, we report a patient who developed agranulocytosis, thrombocytopenia, and severe hepatic dysfunction on day 17 while receiving TZP treatment for an intracranial infection. Bone marrow suppression and hepatic dysfunction are serious adverse effects that should be kept in mind when using long-term TZP.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.